Neurological diseases such as neurodegeneration, pain, psychiatric disorders, stroke and brain cancers would greatly benefit from the use of highly potent and specific peptide pharmaceuticals. Peptides are especially desirable because of their low inherent toxicity.
Introduction
Peptides, proteins and antibodies are of increasing interest to the pharmaceutical industry due to their high potency and selectivity (Serrano Lopez and Lalatsa 2013) . Peptides biodegrade into non-toxic metabolites, possess a minimal potential for drug-drug interactions and are less likely to cause an immunogenic reaction when compared to larger proteins (Van der Walle 2011). These favourable properties have resulted in peptides having a relatively good probability of securing regulatory approval, when compared to low molecular weight drugs (Lax 2010) .
Today the most significant impediment to translating peptides into viable therapies is their overwhelming need for parenteral administration and their short duration of action. Peptides, despite their excellent pharmacological properties, are molecules with poor physical and metabolic stability and peptides have a limited ability to permeate biological membranes; the latter due to their hydrophilicity and comparatively high molecular weight (> 500 Da).
However, despite these limitations, the decreasing number of low molecular weight drugs being approved for clinical use has resulted in an intensification in efforts to find suitable delivery strategies for peptides; delivery strategies that would enable peptides to be converted into medicines. It is interesting to note that peptides now make up 10% of the world's pharmaceutical sales revenues (Reichert 2010 ).
Brain diseases would benefit from the use of highly potent and specific pharmaceuticals with low inherent toxicity and several peptides are being investigated as therapies for neurological diseases, such as neurodegeneration, pain, psychiatric disorders, stroke and brain cancers (Strand 2003) . These neurological diseases are responsible for more than 12% of total global deaths (Masserini 2013) . However for viable peptide neurotherapies to emerge, peptides need to cross the blood brain barrier (BBB) to elicit their response. The BBB, evolutionary designed to maintain brain homeostasis and protect the brain from 5 circulating toxins, prevents over 95% of drugs from accessing the brain (Pardridge 2005) .
Furthermore, the short plasma half life of most peptides means that virtually no peptides show any real brain bioavailability, unless they are transported via specific carriers. As such there are currently no neuropeptide drugs on the market. In essence the delivery of peptides to the brain today would require the use of extremely invasive techniques such as intracerebroventricular infusion, convection-enhanced delivery (Zhou, Patel et al. 2013) , intracerebral injections, the use of intracranial implants or temporary disruption of the BBB by using osmotic agents, ultrasound or by the activation of the bradykinin B2 receptors (Gabathuler 2010) .
Nanoparticle technologies are not widely used in medicine, despite the notable exceptions provided by medicines such as Ambisome, Doxil and Abraxane (Uchegbu and Siew 2013) .
The complexity of nanoparticles as multi-component three dimensional constructs requiring careful design and engineering, detailed analytical methods and reproducible scale-up manufacturing processes to achieve a consistent product with the intended physicochemical, biological and pharmacological properties along with the lack of regulatory standards in the examination of nanomedicines are hindering their translation into the clinic. However preclinical studies abound in which nanoparticles have shown promise in meeting the challenge of peptide delivery (Lalatsa, Schatzlein et al. 2012) . The reasons for the use of nanoparticles to deliver peptides across the blood brain barrier include their small size, which promotes blood residence and hence brain transport of the encapsulated drug (Lalatsa, Lee et al. 2012; Nance, Woodworth et al. 2012) , particle shape as nanofibres have been shown to deliver peptides across the blood brain barrier (Mazza, Notman et al. 2013) and the fact that nanoparticle surfaces may be decorated with various transport ligands to exploit a number of brain endothelial transporters such as: the low density lipoprotein (LDL) receptor related protein 1 & 2, and the transferrin, leptin, insulin and diphtheria toxin receptors (Lalatsa, Schatzlein et al. 2012; Pardridge 2012; Pardridge and Boado 2012) . This 6 review focuses on recent advances in peptide brain delivery with a particular emphasis on the use of nanoparticle technologies. Peptides, for the purposes of this review, are defined as polyamino acid bioactive agents with less than 60 amino acids.
Pathways for the transport of peptides across the blood brain barrier
There are several potential routes by which peptides could cross the blood brain barrier, namely by diffusion, carrier mediated uptake and receptor mediated endocytosis (Figure 1 ).
For diffusion, enhanced lipophilicity is required and for receptor mediated and carrier mediated uptake a transport specific ligand must be incorporated within the peptide medicine.
Weak hydrogen bonding potential (less than 6 hydrogen bonds), lipophilicity (Log D > 2) and a small molecular size (< 500 Da) along with the absence of free rotatable bonds and a polar surface area of < 60 -70 Å are favourable for permeation across the BBB via diffusion (Pauletti, Okumu et al. 1997; Sorensen, Steenberg et al. 1997; Kelder, Grootenhuis et al. 1999; Lennernas and Lundgren 2004) . Thus, passive diffusion of natural peptides is very limited unless the peptides possess an amphipathic structure (Teixido, Belda et al. 2005) or are rendered lipophilic by synthetic means (Batrakova, Vinogradov et al. 2005; Lalatsa, Lee et al. 2012) . The brain capillary endothelial cells rely upon transport proteins to facilitate the entry of essential polar nutrients with polarised expression on either the luminal or abluminal membrane (Brasnjevic, Steinbusch et al. 2009 ). These transport systems are specific for certain small peptides of no less than 10 amino acids (peroxisome Targeting Signal Type 1-5, PTS1 -5), hexoses (glucose transporter 1, GLUT -1), monocarboxylic acids (Protonlinked monocarboxylate transporter, MCT -1), amino acids, organic anions (organic anion-7 transporting polypeptide, OATP) and organic cations (organic cation transporter novel subfamily, OCTN), neurotransmitters and nucleosides. Utilisation of these carrier systems expressed at the BBB is a useful strategy for therapeutic peptide delivery to the brain; however there is a need to attach specific chemical groups to the peptides in order to render them substrates for these endogenous carriers; e.g. the glycosylation of the peptide to enable transport through the GLUT -1 receptors (Bilsky, Egleton et al. 2000; Egleton, Mitchell et al. 2000) . These carrier mediated strategies of peptide transport have been recently reviewed (Brasnjevic, Steinbusch et al. 2009; Lalatsa 2011; Lalatsa, Schatzlein et al. 2012 ) and the carrier system for glutathione (GSH), which is present at the luminal membrane is the only carrier mediated system that has been used for the delivery of nanoparticles (Cacciatore, Baldassarre et al. 2012) .
Endocytosis is the main route of cellular entry for large molecular weight compounds and several peptides have been transported across the BBB via receptor mediated transcytosis (Brasnjevic, Steinbusch et al. 2009 ). Binding of the ligand to its specific membrane receptor on the cell surface induces a modification of the receptor protein and triggers the formation of invaginations; these invaginations may be clathrin coated and in turn trigger the formation of endocytotic vesicles (Broadwell, Balin et al. 1988) . Once within the cell, the ligand containing vesicles can be either exocytosed leading to transport across the BBB, fused with a lysosome leading to intracellular degradation (Broadwell, Balin et al. 1988) , or can bind to a second intracellular receptor as in the case of the transfer of iron from transferrin to intracellular ferritin (Willingham, Hanover et al. 1984) . Once there is dissociation of the ligand from the receptor, the receptor is recycled to the cell surface to participate in further transport events (Gabathuler 2010) . Another minor intracellular pathway may involve trafficking of endosomes, containing intact receptor ligand, to the inner saccule of the Golgi complex, where the enzymes can cause dissociation of the ligand from the receptor, and the separated ligand may then be exported in vesicles destined for lysosomal degradation 8 (Brasnjevic, Steinbusch et al. 2009 ). Exocytosis and the avoidance of the lysosomal pathway may be a special feature of the BBB compared to other types of cells and tissues, as transcytosis of a number of macromolecules is a homeostatic requirement (Abbott, Patabendige et al. 2010) . Receptor-mediated endocytosis across the BBB in vivo has been shown for a few peptides such as insulin (Frank, Pardridge et al. 1986) . Table 1 summarises available receptors for transport of molecules across the BBB. 
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The conjugation of peptide loaded nanostructures to the transport ligands shown in Table 1 is a viable strategy for the delivery of peptides to the brain (Brasnjevic, Steinbusch et al. 2009 ). However when choosing a transport ligand, the ligand should have certain properties: a) it should have sufficiently high affinity for the receptor and yet still enable the release of its cargo in the brain parenchyma, b) the endogenous ligand should not compete with the delivery ligand for receptor occupancy at the BBB, thus a careful consideration of the relative binding affinities and the physiological levels of the endogenous ligand needs to be made
[transferrin is not a suitable ligand as its plasma concentration is >1000 fold higher than the transferrin -transferrin receptor K d (5.6 nM) (Visser, Voorwinden et al. 2004 ), c) the brain uptake of the ligand conjugate should be high enough to allow for a therapeutic dose to reach the brain.
Parenteral Administration
Due to the delivery challenges highlighted above, most experimental neuropeptides have been administered by parenteral routes, i.e. the intravenous route and in some preclinical studies via the intraperitoneal route. Once in the blood these neuropeptides are required to cross the BBB. The brain is 1% of the rodent mass and hence delivery of 1% of the injected dose to the brain at the peak time point, indicates a complete negation of the blood brain barrier in experimental studies. However such levels are rarely achieved and morphine for example, a very effective CNS drug only achieves 0.02% of the dose reaching the rodent brain 30 minutes after subcutaneous injection (Banks and Kastin 1994) . Hence levels of brain delivery in excess of 0.1% of the administered dose, represent a real crossing of the blood brain barrier. A number of methods have been used to achieve brain delivery that can be summarised according to their reliance on endogenous transporters and the biological properties of the nanoparticles.
Carrier Transport Mediated Uptake
The glutathione carrier has been employed in delivering peptides across the BBB in the form of glutathione poly(ethylene glycol) (GSH-PEG) liposomes. When these liposomes were loaded with a synthetic opioid peptide (DAMGO, H -Tyr -d -Ala -Gly -MePhe -Gly -ol) and injected intravenously they prolonged the brain half-life of DAMGO to 6.9 ± 2.3 h, increasing he half life by 4.5 fold when compared to the administration of the free drug (Lindqvist, Rip et al. 2013) . It was found that free DAMGO entered the brain to a limited extent and the use of the GSH -PEG liposomes doubled the brain exposure (Lindqvist, Rip et al. 2013 ).
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Receptor Mediated Uptake
Low-density lipoprotein receptor related protein 1 (LRP1)
A new family of 19 amino acid peptides derived from the kunitz domain of protease inhibitor aprotinin, and known as the Angiopeps, has been shown to facilitate transfer across the BBB by utilising low-density lipoprotein receptor related protein 1 (LRP -1) (Demeule, Currie et al. 2008; Demeule, Regina et al. 2008 ). This technology has been used to deliver both peptides and larger molecules such as 150 kDa antibodies (Gabathuler 2010) . Angiopep -2's (TFFYGGSRGKRNNFKTEEY) positive charge contributes to its binding to the brain endothelial cell surface and after its interaction with LRP -1, the Angiopep -2 -LRP -1 complex is internalised by vesicle formation. LRP-1 is involved in the Angiopeps' mechanism of action, and this distinguishes the Angiopeps from other positively charged peptide transporters such as the cell penetrating peptides (CPPs): transcription activating factor (TAT), penetratin and Syn -B; these CPPs utilise adsorptive-mediated transcytosis (Herve, Ghinea et al. 2008; Bertrand, Currie et al. 2010) . ANG2002 is a conjugate of Angiopep -2 peptide and neurotensin (a 13 amino acid neuropeptide). The transport of ANG2002 across the BBB is higher than that of unconjugated neurotensin and the conjugated neurotensin in ANG2002 retains its affinity for the neurotensin receptor (Demeule, Regina et al. 2010 ).
Using a similar strategy, ANG2006 has been introduced and this is a conjugate of Angiopep -2 with Exendin -4 (glucagon -like peptide -1 agonist); however very limited information is available pertaining to this peptide conjugate (Nikolich 2009). The Angiopep technology is now at a clinical stage and ANG1005 (an Angiopep -2 -paclitaxel conjugate) Thomas, Taskar et al. 2009; Gabathuler 2010 ) is currently being clinically evaluated for the delivery of paclitaxel to brain tumours. 
Low density lipoprotein receptor
Transferrin receptor
ArmaGen OX26, a rat transferrin receptor monoclonal antibody, has been used to successfully target polymersomes and nanoparticles across the BBB. The optimal number of OX26 molecules conjugated to poly(ethylene glycol) -poly(epsilon -caprolactone) (PEG -PCL)
polymersomes was found to be 34 (OX26 34 -PO) and this system resulted in the delivery of 0.14 -0.16% of the intravenously injected dose to the brain (Pang, Lu et al. 2008) . NC-1900 (a vasopressin fragment with neuroprotective properties) was encapsulated into OX26 34 -PO and the NC -1900 -OX26 34 -PO system improved the scopolamine-induced learning and reduced memory impairment in a rat water maze task after intravenous administration (Pang, Lu et al. 2008) . Conjugation of OX26 to poly(ethylene glycol) chitosan nanoparticles also resulted in enhanced brain uptake after intravenous administration of an anticaspase peptide, Z-DEVD-FMK (Aktas, Yemisci et al. 2005) .
A peptide motif obtained from phage display experiments and with a high affinity for transferrin receptors (CGHKAKGPRK, denoted as B6) has also shown potential in enabling the permeation of poly(ethylene glycol) -poly(lactic acid) block copolymer (PEG -PLA) nanoparticles to the brain (Liu, Gao et al. 2013 ). B6 nanoparticles exhibited significantly enhanced cellular accumulation compared to plain PEG -PLA nanoparticles and cellular uptake was achieved via lipid raft-mediated and clathrin -mediated endocytosis. B6 PEG -PLA nanoparticles were loaded with an octapeptide (NAPVSIPQ) derived from an activity dependent neuroprotective protein and which is being trialled clinically in Alzheimer's Disease patients (Gozes, Divinski et al. 2008) . Administration of B6 nanoparticles encapsulating the neuroprotective peptide NAPVSIPQ to Alzheimer's disease mouse models resulted in excellent amelioration of learning impairments, cholinergic disruption, and a reduced loss of hippocampal neurons (Liu, Gao et al. 2013) . 
Leptin receptor
Leptin, a 16 kDa protein produced in white peripheral adipocytes, binds to the leptin receptor in the choroid plexus and on the brain capillary endothelial cells, where it is taken up into the brain parenchyma . The leptin receptor may be saturated in obese patients that have elevated levels of leptin (Kd of the receptor is similar to normal serum levels) (Burgueraa and Couceb 2001) . A leptin 12 -32 fragment, g21, conjugated on the surface of poly(lactic -co -glycolic) acid (PLGA) nanoparticles has been shown to cross the BBB on intravenous injection, with 0.16% of the injected dose of nanoparticles reaching the brain after 2h (Tosi, Badiali et al. 2012) . No anorectic effects were seen in rats after the intravenous administration of 0.03 µg of the g21 transport ligand conjugated to nanoparticles (Tosi, Badiali et al. 2012 ).
Cell Penetrating Peptides
Cell-Penetrating Peptides (CPPs) originate from various families and are heterogeneous in size (10 -27 amino acid residues) and sequence, but they all possess multiple positive charges at physiological pH. Some of them share common features such as an amphipathic sequence and the ability to interact with a lipid membrane (Morris, Deshayes et al. 2008; Eiriksdottira, Konateb et al. 2010) . Examples include the transcription-activating factor (TAT), penetratin and the SynB vectors (family of vectors derived from the antimicrobial peptide protegrin 1). A number of other CPPs are the product of engineering efforts, e.g. the homoarginine vectors, the model amphipathic peptide, transportan and other chimeric peptides such as signal-based peptide (SBP) and the fusion sequence-based peptide (FBP) (Herve, Ghinea et al. 2008 ).
The TAT peptide is a non-amphipathic arginine-rich CPP derived from the TAT protein originating from the human immunodeficiency virus type 1 (HIV -1), a multifunctional viral protein named originally for its intracellular role as a transcriptional activator of viral gene expression (Subrizi, Tuominenb et al. 2013) . The TAT protein is actively released from unruptured, HIV -1 infected cells and is detectable in ex vivo culture supernatants and in the serum of HIV -1 infected individuals (Subrizi, Tuominenb et al. 2013 ). This exogenous TAT is able to enter both uninfected and infected cells, however the precise molecular mechanism by which TAT enters the cells is still unclear. TAT binds to cell-surface heparin sulphate and the binding of the full -length TAT protein to both heparin sulphate proteoglycans and the low -density lipoprotein receptor family has been confirmed (Rusnati, Coltrini et al. 1997; Liu, Jones et al. 2000) . The basic domain of TAT extending from residues 49 to 58 (RKKRRQRRR) includes a highly cationic cluster composed of 6 arginine and 2 lysine residues that play an important role in the translocation of the protein across biological membranes; translocation is aided by the strong cell adherence of this motif and cell binding is independent of cell receptors and of temperature (Subrizi, Tuominenb et al. 2013 ). The guanidinium head group of arginine is required for peptide uptake and is more potent than other cationic groups, such as lysine, histidine or ornithine (Mitchell, Steinman et al. 2000) . The mechanism of cellular penetration, which is often compared to a Trojan horse approach, involves two distinct steps: endocytic uptake followed by endosomal escape (Erazo-Oliveras, Muthukrishnan et al. 2012 ).
Memapsin -2 (β-secretase or BACE) inhibitors are particularly attractive candidates for Amyloid β reduction therapy since β -secretase cleavage of amyloid precursor protein represents the initial step in the biogenesis of Amyloid β. It is hypothesised that the inhibition of this step would lead to the elimination of all steps in the pathogenesis of Alzheimer's disease, but memapsin -2 inhibitors are not able to permeate the BBB. Conjugation of a 12 residue TAT fragment but preferably a 9-residue poly -D -Arginine to a peptide analogue inhibitor of memapsin (Wender, Mitchell et al. 2000) resulted in a 64% reduction of Amyloid β levels after a single intraperitoneal injection (Chang, Koelsch et al. 2004) . Multiple injections to simulate a longer half life of the inhibitor produced maximal inhibition of about 90% in the plasma and about 70% in the brain (Chang, Koelsch et al. 2004 ).
Nanoparticulate drug delivery system possesses distinct advantages for brain drug delivery.
However, their permeation across the BBB is not always therapeutically adequate. Cellpenetrating peptides (CPPs), short peptides that facilitate cellular uptake of various molecular cargoes, would be appropriate candidates for facilitating brain delivery of nanoparticles encapsulating peptides. Examples of the use of CPPs to deliver nanoparticles across the BBB are given below
The SynB peptides (RGGRLSYSRRRFSTSTGR) are a family of cell-penetrating peptides that show charge -mediated BBB selectivity, with uptake proceeding via a caveolaeindependent pathway (Drin, Cottin et al. 2003) . The SynB peptide family is derived from the natural antimicrobial peptide protegrin 1 (PG -1) originally isolated from porcine leukocytes.
PG -1 is an 18 amino acid long peptide with an antiparallel beta-sheet structure stabilized by two disulfide bridges. It interacts with, and forms pores in the lipid matrix of bacterial membranes. Various linear analogues of PG -1 that lack cysteine residues have been designed and these are devoid of the membrane-disrupting activity of PG -1 (Harwig, Waring et al. 1996; Mangoni, Aumelas et al. 1996; Chen, Falla et al. 2000) .
SynB peptides have been used extensively as cationic cell penetrating peptides for low molecular weight actives (Adenot, Merida et al. 2007 ) and for peptides such as dalargin (Rousselle, Clair et al. 2003) ; with transport observed across cell membranes in vitro and across the BBB in vivo when administered intravenously. There have also been recent reports of the use of SynB peptides as brain transport systems for nanoparticles. For example, intravenously injected SynB pegylated gelatin siloxane nanoparticle (SynB -PEG -GS) levels in the brain were significantly higher and levels in the liver significantly lower compared to plain nanoparticles (Tian, Wei et al. 2012 ).
Penetratin, a CPP with a relatively low content of basic amino acids, has been used to functionalize poly(ethylene glycol)-block-poly(lactic acid) (PEG -PLA) nanoparticles and penetratin enhanced the cellular accumulation (Xia, Gao et al. 2012) . In vivo pharmacokinetic and biodistribution studies showed that penetratin nanoparticles exhibited significantly enhanced brain uptake and reduced accumulation in the non-target tissues compared with low molecular weight protamine (a CPP with high arginine content) functionalized nanoparticles (Xia, Gao et al. 2012) .
A thermally responsive elastin like polypeptide (ELP) covalently attached to a cellpenetrating peptide and a therapeutic inhibitory peptide (inhibits the oncogenic c -Myc protein) has been shown to be able to enhance delivery to rat brain tumours and mediate uptake across the tumour cells' plasma membranes on intravenous administration (Table 1 ) (Bidwell, Perkins et al. 2013) . Specifically, when the lead CPP -ELP -fused c -Myc inhibitor was combined with focused hyperthermia of the tumours, an 8 fold increase in tumour polypeptide levels was observed. Additionally an 80% reduction in tumour volume was recorded along with a delayed onset of tumour-associated neurological deficits, a doubling of the median survival time and complete tumour regression in 80% of the animals (Bidwell, Perkins et al. 2013 (Herve, Ghinea et al. 2008) . The use of D-amino acids is one way to enhance the stability of these transport peptides. However, it is critical that when the vector reaches its target it should subsequently degrade or release its cargo in order to elicit its pharmacological response. Toxicity and immunogenicity are also important issues to be considered when translating these brain delivery strategies to the clinic. The full -length TAT protein produced lower levels of neurotoxicity than the shorter peptides TAT (31 -71) and TAT (31 -61) in that order (Herve, Ghinea et al. 2008 ). Both the cysteine -rich domain extending from residues 32 to 47 and the basic domain (positions 48 -57) seem to be essential for neurotoxicity to develop (Herve, Ghinea et al. 2008) . The assessment of the toxicity of unmodified CPPs using a lactate dehydrogenase (LDH)-leakage, DiBAC4(3) -(membrane depolarization), and hemolytic assay showed rather severe toxic effects of transportan 10 as representative of the amphipathic CPPs, but it showed only mild effects of the arginine -rich peptides TAT and penetratin (Tünnemann and Cardoso 2009 ). However, the toxicological properties can be dramatically changed on attachment of low-molecularweight cargoes, for example, labels or other peptides (Tünnemann and Cardoso 2009 
Passive Delivery
Polymeric Nanoparticles:
Peptide brain delivery may also be achieved by using a polymeric or lipid nanocarrier loaded with a hydrophilic peptide. Various examples of such strategies have been reported and the majority of these approaches are exemplified with analgesic peptides ( anti-nociceptive activity demonstrated in a rodent acute pain animal model after both intravenous ) and oral administration ) ( Table 2 ). The anti -nociceptive response in these studies lasted for up to 8 hours.
The ability to elicit a short lived pharmacological effect (30 minutes and 90 minutes) after the administration of dalargin (a mu opioid receptor agonist peptide) loaded poly(butyl cyanoacrylate) nanoparticles coated with either polysorbate 80 or poly(ethylene glycol) (molecular weight = 20 kDa) via the intravenous and oral route respectively has also been shown (Schroeder, Sommerfeld et al. 1998; Das and Lin 2005) . A polysorbate 80 coating of the poly(butyl cyanoacrylate) nanoparticles was critical for dalargin entry into the brain as this coating enables the particles to adsorb Apolipoprotein E from the blood plasma onto the 22 nanoparticle surface and it is this Apolipoprotein E coating that is believed to facilitate transport across the BBB via the LDL -receptor (Kreuter, Shamenkov et al. 2002) .
Vesicles prepared from bolaamphiphiles containing two hydrophilic head groups at each end of a hydrophobic lipidic chain have been used to enhance permeation of small hydrophilic analgesic peptides across the BBB and are characterised by high chemical and physical stability and the ability to be destabilised by esterases leading to changes in the head groups; such head group changes disrupt the vesicular structure and release the encapsulated peptide in tissues with high acetylcholinesterase activity such as the brain (Popov, Abu Hammad et al. 2013) . The presence of chitosan pendant groups appears to enhance antinociception elicited with these bolaamphiphilic vesicles ( Table 2 ). 
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Peptide amphiphiles
Peptides can molecularly arrange into a variety of structures mediated by hydrogen bonding, electrostatic interactions particularly between charged amino acids, hydrophobic associations and π -π stacking (Ulijn and Smith 2008) . Amphipathic peptides possess both hydrophobic and hydrophilic parts and they can be natural peptides (as with penetratin for example), engineered by inclusion of hydrophobic and hydrophilic amino acid mini blocks or by point lipidisation of specific amino acid residues, e.g. by conjugation for example of a hydrophobic alkyl or acyl chain. The distinct separation between the hydrophilic and hydrophobic parts of the molecule drives self-assembly in aqueous environments and the net result is the formation of spherical (Zhang, Marini et al. 2002) , membrane (Zhang, Holmes et al. 1993) , hydrogel (Zhang, Marini et al. 2002) or fibrous aggregates (Zhang, Marini et al. 2002; Mazza, Notman et al. 2013) . Peptide micellar aggregates and nanofibres have been successfully used to deliver peptides across the BBB.
Peptide nanofibres are typically prepared by probe sonication of an aqueous dispersion of the peptide amphiphile. Peptide nanofibres consist of a central hydrophobic core surrounded by a β -sheet of peptides (Paramonov, Jun et al. 2006 ) with the peptide β -sheet wrapped tightly around the hydrocarbon core (Mazza, Notman et al. 2013 ) and the cylindrical assembly primarily driven by the β -sheet. The presence of a β -sheet forming peptide sequence, a charged amino acid and an alkyl chain linked to one end of the peptide have been proposed as critical parameters important for engineering peptide nanofibres (Cui, Webber et al. 2010) . Our group was the first to show that therapeutic peptides could be made to assemble into peptide nanofibres, with the report that the acyl derivatised therapeutic peptide, namely O -palmitoyl tyrosinate ester 1 -dalargin self assembles into nanofibres (Mazza, Notman et al. 2013 ). These nanofibres cross the BBB and produce a pharmacological response on intravenous administration; whereas the peptide dalargin alone is inactive via this route (Mazza, Notman et al. 2013 ). Furthermore peptide nanofibres in which the peptide does not contain a charged amino acid have been produced from Opalmitoyl tyrosinate ester 1 -leucine 5 -enkephalin and this molecule also is active via the intravenous route, where again the peptide alone is inactive. These peptide nanofibres act as a self assembled prodrug, releasing the drug itself from its ester linkage in vivo ( (Lalatsa, Schatzlein et al. 2013; Mazza, Notman et al. 2013) . A passive mechanism of transport for the peptide nanofibers is envisaged due to the increased lipophilicity of the peptide amphiphiles, but the mechanism of transport has not yet been fully elucidated. Peptide nanofibres are a promising delivery strategy for the transport of peptides across the BBB.
Amphiphilic engineered peptides (CGGGRRRRRRTAT) able to form core-shell nanoparticles also demonstrate enhanced antimicrobial activity in a Staphylococcus aureus in vivo meningitis model. Peptide amphiphile spherical aggregates have been prepared by incubation of the peptide amphiphile in aqueous media at 35 °C for 24 hours (Liu, Xu et al. 2009 ).
Oral Administration
Technologies able to ensure non-invasive delivery of peptide and protein therapies to the been demonstrated with opioid peptide analgesics. The first reported strategy able to deliver peptides orally involved the analgesic peptide dalargin, encapsulated in poly(butylcyanoacrylate) nanoparticles coated with either polysorbate 80 (Schroeder, Sommerfeld et al. 1998) or polyethylene glycol (molecular weight = 20 kDa) (Das and Lin 2005) . However, although the intellectual property protection was secured for this technology over 15 years ago (Sabel B. A. and U. 1997) , . Reproduced with permission from reference (Lalatsa, Lee et al. 2012) . 32 barrier, enabling the peptide and the peptide prodrug to cross the BBB (Figure 2) by as yet unclear cellular mechanisms Siew, Le et al. 2012 ). In the case of formulations comprised of the prodrug, the drug is released from the prodrug by plasma, liver and possibly brain esterases (Lalatsa, Lee et al. 2012) .
Developing medicines from endogenous peptides does not require validation of the mechanism of action for the active therapeutic. This is critical if one wishes to avoid the high attrition rates in late clinical development as clinical proof-of concept data is already available. Although commercialisation of peptides as oral therapies is still deemed risky by the pharmaceutical industry, the rewards of niche treatment areas should fuel the development of peptide pill technologies by smaller market entrants.
Intranasal Administration
Nasal delivery is a promising alternative to intravenous injection for the delivery of peptides and proteins as the large surface area and high vascularity of the nasal cavity favours fast absorption of therapeutic molecules into the systemic circulation. However, peptide intranasal bioavailability is considerably less effective than after intravenous administration due to enzymatic degradation or mucociliary clearance, and poor mucosal membrane permeability of large polar substrates (Irwin, Dwivedi et al. 1994 ).
Exploitation of the nasal route for the delivery of drugs to the brain via the olfactory region has been explored as the olfactory region of the nose can be a major site for entry of viruses into the brain (Illum 2000; Reis, Veiga et al. 2008) . In order for a peptide to travel from the olfactory region in the nasal cavity to the cerebrospinal fluid (CSF) or the brain parenchyma, it has to traverse the nasal olfactory epithelium and, depending on the pathway followed, also the arachnoid membrane surrounding the subarachnoid space. Three different pathways across the olfactory epithelium may be envisaged; a) a transcellular pathway, especially across the sustentacular cells, most likely by receptor mediated endocytosis, fluid phase endocytosis or by passive diffusion (unlikely for peptides), b) a paracellular pathway through tight junctions between the sustentacular cells and olfactory neurones and c) via the olfactory nerve pathway where the drug is taken up into the neurons by endocytotic or pinocytotic mechanisms and transported by intracellular axonal transport to the olfactory bulb (Illum 2000) . The transneuronal pathway is very slow and agents reach the CNS as late as 24 hours after administration, hence transport via neuronal routes cannot explain the rapid appearance of drug in the CSF that is seen for a range of low molecular weight compounds (Illum 2000) . Hence, at least in animal models, a therapeutic molecule with moderate lipophilicity, i.e. one that is not so lipophilic so as to give rapid transport into the systemic circulation, will show a higher CSF and olfactory bulb concentration after nasal administration than after parenteral administration (Illum 2000) .
Leucine 5 -enkephalin loaded N -trimethyl chitosan nanoparticles prepared using the ionic gelation method were evaluated as a brain delivery vehicle via the nasal route. Using the Ntrimethyl chitosan gel nanoparticles, there was significant improvement in the observed antinociceptive effect of leucine 5 -enkephalin, as evidenced by the hot plate and acetic acid induced writhing bioassay (Kumar, Pandey et al. 2013) . Polysorbate 80 coated nanoparticles loaded with neurotoxin II (an analgesic peptide which was separated from the venom of Naja atra) also resulted in enhanced antinociception after intranasal delivery (Ruan, Yao et al. 2012 ).
Thyrotropin-releasing hormone (TRH) is reported to have anticonvulsant effects in epileptic patients but is unable to cross the BBB and is rapidly metabolised in the periphery. The intranasal administration of TRH loaded poly (D,L -lactic acid) nanoparticles reduced the frequency and severity of seizures in a rat seizure model. (Kubek, Domb et al. 2009; Veronesi, Aldouby et al. 2009 ).
Coating particles with brain endothelial cell transport ligands has also been explored via the intranasal route. Lactoferrin, a natural 80 kDa iron binding cationic glycoprotein of the transferrin family, consists of a single-chain glycoprotein folded into two globular lobes and lactoferrin is expressed in various tissues and involved in various physiological processes, such as iron uptake by the intestinal mucosa and acting as a bacteriostatic agent (Lönnerdal and Iyer 1995; Suzuki, Lopez et al. 2005) . Extensive histological studies revealed that the lactoferrin receptor is highly expressed in brain endothelial cells and neurons and overexpressed in the CNS in age-related neurodegenerative diseases including Alzheimer's Disease, Parkinson's disease, Huntington's disease and amyotrophic lateral sclerosis (Liu, Jiang et al. 2013) . Furthermore, lactoferrin is more efficiently taken up by the brain tissue than both transferrin and OX26 (Ji, Maeda et al. 2006) . The intranasal administration lactoferrin conjugated poly(ethylene glycol) -block -poly(epsilon caprolactone) (PEG -PCL) nanoparticles loaded with the neuroprotective peptide NAPVSIPQ produced superior results to NAPVSIPQ loaded onto plain PEG -PCL nanoparticles. Pharmacological activity was evaluated in a rat Morris water maze experiment (Liu, Jiang et al. 2013 ). The behavioural pharmacodynamic activity improvements were supported by the evaluation of acetylcholinesterase activity, choline acetyltransferase activity and neuronal degeneration in the mice hippocampus (Liu, Jiang et al. 2013 ).
Another successful nasal strategy involved PEG -PLA nanoparticles modified with wheat germ agglutinin loaded with vasoactive intestinal peptide. This formulation resulted in enhanced brain uptake and improvements in spatial memory in ethylcholine aziridiumtreated rats following the intranasal administration of 25 g kg -1 and 12.5 g kg -1 of vasoactive intestinal peptide loaded on unmodified nanoparticles and wheat germ agglutininmodified nanoparticles, respectively (Gao, Wu et al. 2007 ). An intranasal peptide delivery system was also developed by conjugation of odorranalectin (MW = 1700 Da, a leptin like peptide) to cubosomes via a non-covalent streptavidin -biotin "bridge". Odorranalectin retained its bio -recognitive activity and enhanced the nose to brain delivery of Gly 14 Humanin (a neuroprotective peptide) (Wu, Li et al. 2012) . Pharmacodynamics effects were measured in a Morris water maze test and by acetylcholinesterase activity (Wu, Li et al. 2012 ).
TAT peptides have also been utilised via the intranasal route. TAT-NBD, a 22 amino-acid CPP containing the nuclear factor kappa B (NF -κB) IKKγ -Binding Domain coupled to the transduction sequence of the HIV -TAT protein, is a potent NF-κB inhibitor that attenuates inflammatory responses (Yang, Sun et al. 2013 ). Yet, intravenous delivery of TAT -NBD peptides still requires a high dose to cross the BBB to reach the central nervous system; such a high dose may weaken general immunity and increase the risk of severe infection (Yang, Sun et al. 2013) . In an attempt to reduce the required dose, intranasal delivery of TAT -NBD peptides was carried out in two animal models of neonatal infection sensitised hypoxic-ischemic brain injury. Kinetic experiments showed that TAT -NBD peptides entered the olfactory bulbs rapidly (within 10 -30 min) and peaked in the cerebral cortex around 60 min after the intranasal application in P7 rats (Yang, Sun et al. 2013) . Further, intranasal delivery of 1.4 mg kg -1 TAT -NBD, which is only 7% of the intravenous dose, markedly attenuated NF-κB signalling, microglia activation, and the brain damage triggered by hypoxic ischemia (following a 4 or 72 h exposure to the bacterial endotoxin lipopolysaccharide) (Yang, Sun et al. 2013 ).
Intranasal to the brain peptide delivery strategies have not only been the subject of preclinical experiments but have been exploited in clinical studies and even resulted in the launch of peptide products. Peptides such as melanocortin (4-10), angiotensin II, argininevasopressin, cholecystokinin -8, oxytocin and insulin have been successfully delivered to the brain in human trials (Table 2) Controlling neurological conditions will continue to be at the forefront of therapeutic strategies for the foreseeable future. The possibility of delivering medicines containing drug compounds that do not usually distribute to the brain, by using the technologies and approaches described above, means that new medicines will emerge to tackle these rather challenging conditions.
